Establishing the comparative performance of a drug product is a pivotal step in its development journey. Whether you’re entering a competitive therapeutic class or seeking to improve on an existing treatment, proving that your product meets or exceeds the performance of alternatives already available on the market is critical to regulatory approval, clinical success, and patient trust. But performing comparative assessments like these is far from straightforward. From ensuring analytical equivalence and bioavailability to interpreting complex datasets, comparator product testing demands a combination of technical precision and strategic insight.
The Eurofins BioPharma Product Testing (BPT) network of laboratories provides robust comparator product testing for new and existing pharmaceutical products in terms of quality, safety, and efficacy.
We’ve successfully tested more than 100 marketed drugs across various therapeutic areas, from anti-inflammatories and antidepressants to antiretrovirals and metabolic disorder treatments.
Beyond laboratory data, we help you navigate every phase of comparator testing. Our scientific teams provide the technical consultation needed to address product-specific challenges, helping you interpret complex results and translate them into clear, actionable insights for development or regulatory strategy.
Whether you are preparing a biosimilar, generics submission, or comparative clinical study, Eurofins BPT offers:
We test widely used reference products including atorvastatin, duloxetine, metformin, paracetamol, simvastatin, and many more. Some of the products we have experience with are shown at the bottom of this page (non-exhaustive list).
Eurofins BPT provides more than just data. You gain a partner committed to helping you confidently demonstrate equivalence, satisfy regulatory expectations, and accelerate your time to market.